Key result
Surgery remains the standard treatment for mitral regurgitation, while the MitraClip device is an effective alternative for selected patients at high or prohibitive surgical risk.
Surgical repair remains the gold standard for mitral regurgitation, with transcatheter options like MitraClip reserved for patients at high or prohibitive surgical risk.
Supports risk-based treatment selection for mitral regurgitation; leaves open need for updated comparative trials with newer devices.
Mitral regurgitation (MR) is the second most common valvular heart disease after aortic valve stenosis. With increased understanding of the heterogenic pathophysiology of MR, cardiac surgeons have developed various techniques that increase the likelihood of successful mitral valve repair (MVR). Nowadays, a rate of repair >90% may be reached in some mitral valve reference centres. In recent years, the introduction of transcatheter mitral valve intervention techniques has opened up new frontiers in mitral therapy, specifically in patients at high risk for standard surgery. Current percutaneous technologies for MVR have been developed on the basis of some of the surgical principles. Based on current evidence, surgery remains the standard treatment for MR according to very long-term survival and durability of MVR using Carpentier's technique. Today, in clinical practice, only the MitraClip device may be considered as a real and effective alternative in selected patients with high or prohibitive risk for surgery.
No takes yet. Share an insight, caveat, or question.
Fattouch et al. (2015) conducted a review in Mitral regurgitation. Mitral valve repair (surgical and transcatheter) was evaluated. Surgery remains the standard treatment for mitral regurgitation, while the MitraClip device is an effective alternative for selected patients at high or prohibitive surgical risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: